Unbiased Analysis of Today's Healthcare Issues
Let’s say that you have an international clinical trial that shows a new drug (SuperDrug) perform better than the previous standard of care (OldDrug). Also assume that individuals with a specific comorbidity–let’s call it EF–respond less well to the SuperDrug treatment. If you live in a country where comorbidity EF is common, how well do…
Defining which cancer treatments are the “best” is not as easy as you think. At first glance, treatments that produce the largest survival gains should be considered best. Most cancer treatments come with serious side effects. Thus, new treatments that better improve survival may also increase the risk of adverse events (although in some cases–like…
Did you ever wonder what is is like having lung cancer? Or narcolepsy? What factors are most important to patients when receiving treatment for these diseases? The FDA is working to collect these answers to help guide their drug approval process. The FDA’s “Voice of the Patient” aims to “…more systematically gather patients’ perspectives…
What role do health economists at the UK’s National Institute for Health and Clinical Excellence (NICE) play and how do they conduct their cost effectiveness analyses for new treatments? I answer this question today based on NICE’s own documents. According to their guidelines manual, the role of the health economist in clinical guideline development is to:…
According to Fuchs and Millstein, here’s why: Insurers hesitation to standardize coverage. Standardization of coverage would force insurance companies to compete primarily on the basis of price, which would put pressure on their profits. Employers bear too much of the marginal cost from employees choosing expensive health plans. Because companies wish to avoid alienating employees,…
As part of Health Reform, the government created the a center to study clinical effectiveness of different health treatments. This center, known as the Patient-Centered Outcomes Research Institute (PCORI), “does not have the power to mandate or even endorse coverage rules or reimbursement for any particular treatment.” What leverage does the Institute have? Not too…
According to Kathleen Lohr, the most pressing issues for comparative effectiveness research (CER) include: 1) how to conduct CER for heterogeneous patient populations and 2) ways to implement longitudinal investigations to capture long-term health outcomes. Today I will focus on measuring patient heterogeneity. Although it makes sense to take into account differences across patients, measuring…
Comparative Effectiveness Research (CER), as it name suggests, compares how well different medicines treat a given disease. Politicians claim that using CER findings can help improve quality and decrease cost. If one treatment produces better health outcomes on average than another and also costs less, we should always make people use that treatment, right? Not…
Comparative Effectiveness has been a hot topic in health services research. According to a recent article in the New England Journal of Medicine, “the American Recovery and Reinvestment Act of 2009 authorizes the expenditure of $1.1 billion to conduct research comparing ‘clinical outcomes, effectiveness, and appropriateness of items, services, and procedures that are used to…